LLY vs AZN stock comparison
ELI LILLY & Co vs. Astrazeneca · data as of November 13, 2026
ELI LILLY & Co (LLY) has a market value of about $1.36T, Astrazeneca (AZN) about $286.0B. Over their latest twelve months ELI LILLY & Co had revenue of $86.5B and Astrazeneca $62.4B.
On our five checks ELI LILLY & Co scores higher: 3.4 out of 5 (good) against 2.8 (average).
By area, the stronger company is Astrazeneca on value; ELI LILLY & Co on future growth; ELI LILLY & Co on track record.
Astrazeneca is cheaper on earnings (P/E 26.1 vs. 46.9), while ELI LILLY & Co grew revenue faster over five years (21.6% vs. 17.2% a year).
ELI LILLY & Co leads on 12 of the compared lines and Astrazeneca on 11.
Side by side
| LLY | AZN | |
|---|---|---|
| Size and price | ||
| Market cap | $1.36T | $286.0B |
| Share price | $1,443.50 | $184.45 |
| Score | ||
| Overall score (of 5) | 3.4 | 2.8 |
| Value | 0 | 1 |
| Future growth | 5 | 2 |
| Track record | 5 | 4 |
| Financial health | 3 | 3 |
| Shareholder returns | 4 | 4 |
| Valuation | ||
| P/E (TTM) | 46.9 | 26.1 |
| Forward P/E | 30.4 | 16.5 |
| Price / free cash flow | 69.1 | 46.9 |
| Price / sales | 15.7 | 4.6 |
| EV / EBITDA | 37.1 | 14.7 |
| PEG | 1.70 | 1.20 |
| DCF value vs. price | −37% | −38% |
| Business | ||
| Revenue | $86.5B | $62.4B |
| Net income | $27.6B | $11.0B |
| Free cash flow | $19.7B | $6.1B |
| Net margin | 31.9% | 17.7% |
| Gross margin (5-yr avg.) | 78.9% | 76.8% |
| ROIC (5-yr avg.) | 22.9% | 8.4% |
| Growth | ||
| Revenue growth (1 yr) | 44.7% | 8.6% |
| Revenue growth (5 yrs, per year) | 21.6% | 17.2% |
| EPS growth (5 yrs, per year) | 27.6% | 21.8% |
| Balance sheet and payouts | ||
| Net cash (cash minus debt) | -$44.6B | -$26.0B |
| Dividend yield | 0.48% | 1.74% |
| Shareholder yield | 0.8% | 1.9% |
| Analysts | ||
| Upside to average target | +1% | +13% |
| Consensus rating | Buy | Buy |
Highlighted = the better figure on that line. Revenue, net income and free cash flow: LLY TTM to September 30, 2026, AZN TTM to September 30, 2026. Not investment advice.
Frequently asked questions
Which is the better stock, ELI LILLY & Co or Astrazeneca?
We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) ELI LILLY & Co scores 3.4 out of 5 and Astrazeneca 2.8; the table shows where each one is stronger.
Is ELI LILLY & Co cheaper than Astrazeneca?
On trailing earnings, Astrazeneca trades at a P/E of 26.1 and ELI LILLY & Co at 46.9, so Astrazeneca is cheaper by this measure. A lower P/E can also reflect slower expected growth.
Which grows faster, ELI LILLY & Co or Astrazeneca?
Over five years ELI LILLY & Co grew revenue about 21.6% a year and Astrazeneca about 17.2% a year.
Which pays a higher dividend?
ELI LILLY & Co yields 0.48% and Astrazeneca 1.74%.
Full ELI LILLY & Co analysis → Full Astrazeneca analysis →
More comparisons
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.